Germany's New High-Risk Assessment Medtech Scheme Off To Slow Start
Executive Summary
Germany's new testing and treatment methods (NUBs) scheme for assessing benefit in high-risk products for inpatient use recently processed its first batch of applications. But, as with its longer-established outpatient products counterpart, it does not seem to be an instant success, says German reimbursement expert Ben Modley.
You may also be interested in...
Germany – Still Europe's Stand-Out Medtech Innovation Market
Germany's introduction of benefit assessments for class IIb and class III medical devices, and the impending EU Medical Device and IVD Regulations will place an unquantified strain on medtech manufacturers in Europe's largest market. But new innovation schemes are adding more dimensions for businesses locally.
German Ambulatory Fast-Track Reimbursement Scheme Failing to Deliver
Germany’s system for fast-tracking selected, insufficiently proven ambulatory medtech products into commercial use seems to be falling short of its potential. This has set alarm bells ringing in an industry that is already concerned about its inpatient pass-through scheme (NUBs).
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.